Abstract

Systemic mastocytosis (SM) is characterized by pathologic expansion and activation of mast cells. The main clinical manifestations of SM include skin involvement, gastrointestinal symptoms and anaphylaxis due to the release of its mediators. Thirty percent of pat ients with SM have a low bone mass and 20% fractures. At the same time, SM affects 10% of male patients with idiopathic osteoporosis. Measuring serum tryptase is essential for the screening of MS. We report two cases of SM with bone involvement. A 25-year- old woman with prior diagnosis of SM, based on skin involvement, flushing, high serum tryptase and compatible bone marrow (BM) biopsy and genetic study. Low bone mass was diagnosed and treatment was started with calcium and vitamin D plus oral bisphosphona tes with adequate response. A 47 years old man who presented with multiple osteoporotic vertebral fractures and low bone mass. Treatment with vitamin D and alendronate was started, but the patient developed new vertebral fractures. The study was extended w ith measurement of serum tryptase that was elevated. Diagnosis of SM was confirmed with BM biopsy and the patient was referred to hematology for specific care. These cases emphasize the importance of bone assessment in SM, as well as the need to rule out S M in patients with osteoporosis and no evident cause.

Highlights

  • Systemic mastocytosis (SM) is characterized by pathologic expansion and activation of mast cells

  • We report two cases of SM with bone involvement

  • The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis

Read more

Summary

Casos clínicos

Caso 1 Mujer de 25 años, sin antecedentes previos de importancia. A los 23 años presentó lesiones cutáneas eritematosas solevantadas en extremidades inferiores y tronco con signo de Darier positivo, asociadas a lipotimia y flushing al exponerse a calor. Se complementó estudio con triptasa sérica que resultó en 40 ng/ml (valor normal (vn) ≤ 11,4 ng/ml). Se solicitó densitometría ósea (DXA) que mostró DMO en L2-L4 0,880 g/cm[2] (Z score -2,3) y en cuello femoral de 0,719 g/cm[2] (Z score -2,1). Caso 2 Hombre de 47 años que consultó por fracturas vertebrales múltiples sin traumatismo identificable (L1, L2 y L4). Se solicitó DXA que mostró DMO en L2-L4 de 0,896 g/cm[2] (Z score-2,6) y de 0,795 g/cm[2] (Z score-1,5) en cuello femoral. El control con DXA al año de tratamiento mostró mantención de DMO en columna lumbar con aumento de 6% en cuello femoral. Se repitió estudio de causas secundaria, agregando esta vez medición de triptasa sérica que resultó en 42,6 ng/ml.

Electroforesis de proteínas
Findings
Conclusión
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call